Table 2.
Response rate
| Overall | Standard | Bi-weekly | |
|---|---|---|---|
| N = 88 | N = 40 | N = 42 | |
| Best overall response, n (%) | |||
| Complete response | 2 (2.3) | 1 (2.5) | 1 (2.4) |
| Partial response | 15 (17.0) | 7 (17.5) | 8 (19.0) |
| Stable disease | 23 (26.1) | 9 (22.5) | 13 (31.0) |
| Stable disease ≥ 6 months | 6 (6.8) | 2 (5.0) | 4 (9.5) |
| Progressive disease | 37 (42.0) | 21 (52.5) | 15 (35.7) |
| Not evaluable | 5 (5.7) | 0 | 1 (2.4) |
| Objective response rate, n (%) | 17 (19.3) | 8 (20.0) | 9 (21.4) |
| 95% CI | 11.7–29.1 | 9.1–35.6 | 10.3–36.8 |
| Clinical benefit rate, n (%) | 23 (26.1) | 10 (25.0) | 13 (31.0) |
| 95% CI | 17.3–36.6 | 12.7–41.2 | 17.6–47.1 |
| Time to treatment failure, days | 77 | 75 | 81.5 |
| 95% CI | 70–95 | 69–119 | 73–107 |
| Overall survival, days | 427 | 412 | 523 |
| 95% CI | 300–701 | 275–713 | 350–828 |
CI confidence interval